148 related articles for article (PubMed ID: 9292548)
1. In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype.
Halverson DC; Schwartz GN; Carter C; Gress RE; Fowler DH
Blood; 1997 Sep; 90(5):2089-96. PubMed ID: 9292548
[TBL] [Abstract][Full Text] [Related]
2. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
3. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
[TBL] [Abstract][Full Text] [Related]
4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
5. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes.
Vukmanovic-Stejic M; Vyas B; Gorak-Stolinska P; Noble A; Kemeny DM
Blood; 2000 Jan; 95(1):231-40. PubMed ID: 10607707
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
Vinay DS; Kwon BS
Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
[TBL] [Abstract][Full Text] [Related]
7. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection.
Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH
Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
9. Non-host-reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection.
Fowler DH; Whitfield B; Livingston M; Chrobak P; Gress RE
Blood; 1998 Jun; 91(11):4045-50. PubMed ID: 9596648
[TBL] [Abstract][Full Text] [Related]
10. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization and modulation of cytokine production by CD8+ T cells from human immunodeficiency virus-infected individuals.
Maggi E; Manetti R; Annunziato F; Cosmi L; Giudizi MG; Biagiotti R; Galli G; Zuccati G; Romagnani S
Blood; 1997 May; 89(10):3672-81. PubMed ID: 9160672
[TBL] [Abstract][Full Text] [Related]
13. The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity.
Kemp RA; Bäckström BT; Ronchese F
Immunology; 2005 Jul; 115(3):315-24. PubMed ID: 15946249
[TBL] [Abstract][Full Text] [Related]
14. Type 1 Cytotoxic T Cells Increase in Placenta after Intrauterine Inflammation.
Liu J; Liu Y; Panda S; Liu A; Lei J; Burd I
Front Immunol; 2021; 12():718563. PubMed ID: 34566975
[TBL] [Abstract][Full Text] [Related]
15. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
Helmich BK; Dutton RW
J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
[TBL] [Abstract][Full Text] [Related]
16. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
17. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
19. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
Li L; Sad S; Kägi D; Mosmann TR
J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
[TBL] [Abstract][Full Text] [Related]
20. Relative diabetogenic properties of islet-specific Tc1 and Tc2 cells in immunocompetent hosts.
Vizler C; Bercovici N; Heurtier A; Pardigon N; Goude K; Bailly K; Combadière C; Liblau RS
J Immunol; 2000 Dec; 165(11):6314-21. PubMed ID: 11086068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]